A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Entospletinib With and Without Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia
Latest Information Update: 28 Dec 2021
At a glance
- Drugs Entospletinib (Primary) ; Tirabrutinib (Primary) ; Obinutuzumab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 29 Oct 2020 Status changed from active, no longer recruiting to completed.
- 08 Sep 2020 Planned End Date changed from 1 Sep 2020 to 1 Oct 2020.
- 06 Nov 2019 Results assessing tirabrutinib and entospletinib as dual therapy (TE), and as triple therapy in combination with obinutuzumab (TEO) released at the 61st Annual Meeting and Exposition of the American Society of Hematology